Hospital acquired disease or nosocomial infection is a localized or systemic condition in patients occurred due to adverse reaction caused by infectious toxin agents under medical care and were absent at the time of admission. Hospitals acquired infections results in prolonged hospital stay, antimicrobial resistance, long-term disabilities, and increase mortality rate. Pathogens responsible for nosocomial infections include viruses, fungal parasites, and bacteria.
Hospital acquired infection is emerging as a major burden for society, patients, and healthcare management
Hospital acquired disease could be catheter-related blood stream infection, surgical site infection, ventilator-associated pneumonia, and catheter-associated urinary tract infection. These infection occurring in emerging economies globally. According Asia Pacific Journal of Tropical Medicine, 2017, Nosocomial infections account for around 10% in emerging economies and around 7% in developed economies out of all the infections. According to the World Health Organization (WHO), 2011, approximately around 15% patients hospitalized suffer from above mentioned infections, due to exposure to pathogens through different sources, such as healthcare staff and infected patients. Newborns, especially in emerging economies are also at high risk to develop hospital acquired infection. According to WHO, 2011, the infection rate in newborns is 20 times higher in emerging economies as compared to high income economies.
Hospital acquired infection is emerging as a major burden for society, patients, and healthcare management. Nosocomial infections could be prevented by practicing infection control programs and adopting antimicrobial control policies. For instance, National Health & Medical Research Council Australia (NHMRC), 2002 provided critical guidelines for the management of infections, prevention, and control in healthcare organizations.
The global hospital acquired disease testing market was valued at US$ 539 million in 2016 and is expected to witness a robust CAGR of 19.70% over the forecast period (2017 – 2025).
Antibodies resistance and extended hospitalization is expected to propel growth of hospital acquired disease testing in the near future
High prevalence of nosocomial infections such as surgical wounds, urinary tract infections, and lower respiratory tract infections in intensive care units, orthopedic, and acute surgical ward fuels growth of hospital acquired disease testing market. The technique used for preventions, diagnosis, and testing of hospital acquired diseases are microarray, PCR, and solid phase hybridization. The urinary tract infections is most common in patients dwelling with urinary catheter, as urethra is located close to the anus, which increases the changes of invasions of bacteria from large intestine into the urinary tracts. Therefore, expenses and antibiotic resistance increases with extended hospitalization, which in turn propels growth of hospital acquired disease testing market.
Factors such as favorable government initiatives towards nosocomial infections, regulatory guidelines and reimbursement scenario are expected to boost the hospital acquired disease testing market in North America and Europe. For instance, medicare and private insurance companies are eliminating the reimbursement rate due to high rate of hospital acquired infection (HAI) incidence during 2014-2015, adding economic pressures on hospitals to reduce hospital acquired diseases. However, unhygienic conditions and practices in developing and underdeveloped regions is resulting in higher incidences of HAI in these regions. Thus, there is urgent requirement for HAI testing in these regions during the forecast period.
The key market players are Diatherix laboratories, Life technologies, Cantel Medical Corporation Meridian Biosciences, Qiagen GmbH, Nordion, Roche, and Cepheid & others.